FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007913595> ?p ?o ?g. }

• W2007913595 endingPage "e158" @default.
• W2007913595 startingPage "e158" @default.
• W2007913595 abstract "Mutations in CSF3R have been recently defined as the common genetic event in patients with myeloid neoplasms, including the rare entity known as chronic neutrophilic leukemia (CNL),1, 2, 3 becoming a potentially useful biomarker for diagnosing and therapy target.4 CSF3R encodes the transmembrane receptor for granulocyte colony-stimulating factor (G-CSF; CSF3), which provides the proliferative and survival signal for granulocytes and also contributes to their differentiation and function.5 Although there are several studies on massive next-generation sequencing of myeloid disorders, not a single comprehensive study has been reported in CNL. Here, we used whole-exome sequencing (WES) and RNA sequencing (RNA-seq) to identify new candidate genes to the disease pathogenesis of an index CNL patient.A 66-year-old man was diagnosed with CNL, according to the 2008 World Health Organization (WHO) classification. At diagnosis, the patient presented peripheral blood leukocytosis (66 × 109/l), segmented neutrophils and band forms were 91.5% of the white blood cells counts (WBCs), immature granulocytes were <10% of WBCs and myeloblasts were <1%. The aspirate showed a hypercellular bone marrow (BM) with neutrophilic granulocytes increased in number and percentage and myeloblasts 0.5% of WBCs. No dysplastic features were observed in the myeloid lineages. His Zubrod Performance Status (ECOG) was 1. A GTG-banding chromosome analysis revealed a normal karyotype (46,XY[20]), and molecular biology studies were negative for BCR-ABL1 transcripts and JAK2 V617F mutation. The patient was treated with hydroxyurea but, unfortunately, died 7 months after the diagnosis due to an intensification of the disease.To improve our understanding of the genes involved in the pathogenesis of CNL, WES was performed on matched tumor and oral mucosa cell (germline) samples from the patient. Candidate somatic mutations were identified using RUbioSeq software.6 The bioinformatics analysis and the filtering steps to identify the coding variants are detailed in the Supplementary Material. In total, we found 1437 candidate variants; among them, 797 were somatic mutations (412 were intronic, intergenic, affecting non-conding-RNA or untranscribed regions and 385 were exonic). From the 385 exonic variants, we selected only those variants within coding regions that, after passing sequencing depth and quality filters, were, frameshift, stop gain/loss and non-synonymous amino acid changes predicted to produce a deleterious effect in the protein structure, resulting in 56 single-nucleototide variants (SNVs) and small insertions/deletions (indels). We selected 24 for further validation by Haloplex/Ion Torrent. In addition to the CSF3R p.Thr618Ile mutation, we validated mutations in U2AF1, TET2, LUC7L2 and ASXL1 (Figure 1a and Table 1).Figure 1Molecular characterization of CNL. (a) In addition to the CSF3R T618I mutation, WES revealed mutations in U2AF1, TET2, LUC7L2 and ASXL1. LUC7L2 mutation was found in homozygosis; (b) LOH of 53.2 Mb in chromosome 7q including the locus of LUC7L2 ...Table 1Description of validated mutations in the CNL patientThe current study, first, confirms the observations by Maxon et al.1 and Pardanani et al.2 regarding the association between CNL and CSF3R mutations. Second, it presents a complete picture of the mutational profiling of CNL, certainly more complex than expected from these previous reports. In fact, we found and validated mutations affecting both splicing machinery and epigenetic genes. Kosmider et al.,3 very recently, showed that CSF3R somatic mutations can be identified in ∼4% of chronic myelomonocytic leukemias. These mutations, which affect distinct residues in CSF3R as compared with CNL, are frequently associated with mutations in the ASXL1 gene and have a poor prognostic impact on overall and acute myeloid leukemia (AML)-free survival. Together, these data indicate that CNL genome had a combination of few mutations with a pattern of cooperation with a strong biological relationship among genes and categories, similar to AML.7 Along this line of cooperating mutations on epigenetic genes, we also found in our CNL patient mutated copies of ASXL1 and TET2 genes.The variant allelic frequency of LUC7L2 mutation was found to be high (more than 95%). We previously described mutations of this gene in myelodysplastic syndrome (MDS).8 As this gene is located in the 7q region, a frequently deleted chromosomal region in myeloid leukemias,9 we decided to investigate whether a critical deletion or a loss of heterozygosity (LOH) affecting this genomic region was also present in the patient. To study this phenomenon, we interrogate our WES data for the LOH across the whole genome of the sample. Interestingly, we found an LOH of 53.2 Mb in chromosome 7q including the locus of the LUC7L2 gene. Allele frequencies of each SNP along chromosome 7 are shown in Figure 1b and Supplementary Figure 4. As no del(7q) was detected with metaphase cytogenetics, our study demonstrates for the first time mutations in LUC7L2 accompanied by a copy-neutral LOH (uniparental disomy) in 7q in a patient with an aggressive CNL phenotype. To further evaluate the biological consequences of this homozygous mutation, we explored LUC7L2 expression in the BM cells of the patient and in some myeloid leukemia cell lines (Figure 1c). By using real-time PCR, we observed a downregulation in the expression of LUC7L2 in the patient cells compared with normal granulocytes, as well as a general downregulation in myeloid leukemia cell lines.To determine the functional consequences of the mutations in LUC7L2 and U2AF1, genes involved in the splicing machinery, in the proper splicing process, we performed RNA-seq in our index patient as well as in CD34+ cells from a normal control BM. Although no clear genome-wide increase in intron retention was observed in the patient, as previously reported by us10 in some MDS cases, we found an altered pattern of splicing in the mRNA species transcribed from the RUNX1 gene. At the 3′ splice site of RUNX1 intron 5, the un-spliced reads were almost three times more frequent in the mutated patient than in the normal control (Supplementary Figure 1). Because of the large numbers of diverse mutations in the splicing machinery, larger studies will be needed to fully evaluate the impact of these mutations in splicing.In relation with the effects of an aberrant RNA splicing due to the presence of two mutations in the genes responsible for these processes, we used RNA-seq data to investigate the presence of aberrant fusion transcripts in our CNL patient. In fact, we identified a chimeric transcript involving the PIM3 and SCO2 genes (both were located on 22q13.33), which was the result of an intrachromosomal inversion of approximately 0.6 Mb in chromosome 22 (Figure 1d). The PIM3 oncogene belongs to the Ser/Thr protein kinase family and PIM subfamily. This gene is overexpressed in hematological and epithelial tumors and is associated with MYC co-expression. It has a role in the regulation of signal–transduction cascades, contributing to both cell proliferation and survival, and provides a selective advantage in tumorigenesis.11 Interestingly, the inhibition of PIM kinases by pim kinase inhibitors in Myc-induced lymphoma resulted in cell death.12 Functional studies are needed to elucidate the role of this fusion gene in leukemogenesis.Regarding the global expression profile of CNL, we obtained 2022 genes upregulated and 1884 genes downregulated in CNL compared with the control (FDR=0.05). Functional classification of genes differently expressed between CNL cells and CD34+, according to the Ingenuity Systems Analysis (Ingenuity Systems, www.ingenuity.com), revealed an enrichment of categories like cell signaling, cell death and survival, as well as gene expression (B-H P-value <0.05; Supplementary Figure 2). These findings reconfirmed the significant pathophysiology of such several synergetic unique genetic defects in the general CNL cohort, as well as in our index case.The oncogenic CSF3R mutations T618I strongly activate the JAK/STAT pathway and are sensitive to inhibitors of SRC family TNK2 and JAK kinases and may provide a new avenue for therapy.4 In contrast, pim kinase inhibition could be a viable treatment strategy in certain human leukemias that rely on the PIM3 kinase expression.12 In addition, epigenetic modifiers provide new targets for therapeutic intervention, and targeting these enzymatic activities is currently being explored from a therapeutic standpoint in several types of leukemia.13, 14 Although Pardanani et al.,2 considering 35 cases of clinically suspected CNL, did not found alteration in the survival on the basis of the presence or absence of CSF3R mutations, our reported patient had a rapid disease progression and died 7 months after diagnosis, which was probably explained by the profoundly aberrant landscape of gene mutations and rearrangements with functional effects on the biology of the tumor cells.In summary, our study provides, for the first time, a massive molecular and expression data, revealing a large amount of genomic alterations in CNL. In this complex scenario, a combination of new target therapies may be considered as reasonable options for the therapeutic management of this aggressive and rare subtype of leukemia." @default.
• W2007913595 created "2016-06-24" @default.
• W2007913595 creator A5001811866 @default.
• W2007913595 creator A5009021448 @default.
• W2007913595 creator A5010765538 @default.
• W2007913595 creator A5021121886 @default.
• W2007913595 creator A5036293904 @default.
• W2007913595 creator A5041566320 @default.
• W2007913595 creator A5050620740 @default.
• W2007913595 creator A5053487646 @default.
• W2007913595 creator A5053607123 @default.
• W2007913595 creator A5079168682 @default.
• W2007913595 creator A5081862103 @default.
• W2007913595 creator A5085974329 @default.
• W2007913595 date "2013-11-08" @default.
• W2007913595 modified "2023-10-18" @default.
• W2007913595 title "CSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia" @default.
• W2007913595 cites W1255676896 @default.
• W2007913595 cites W2017013844 @default.
• W2007913595 cites W2043776462 @default.
• W2007913595 cites W2046766666 @default.
• W2007913595 cites W2068069990 @default.
• W2007913595 cites W2079800026 @default.
• W2007913595 cites W2092611859 @default.
• W2007913595 cites W2094640639 @default.
• W2007913595 cites W2116120463 @default.
• W2007913595 cites W2153597111 @default.
• W2007913595 cites W2155046477 @default.
• W2007913595 cites W2164302505 @default.
• W2007913595 cites W2167750080 @default.
• W2007913595 doi "https://doi.org/10.1038/bcj.2013.55" @default.
• W2007913595 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3880438" @default.
• W2007913595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24212483" @default.
• W2007913595 hasPublicationYear "2013" @default.
• W2007913595 type Work @default.
• W2007913595 sameAs 2007913595 @default.
• W2007913595 citedByCount "15" @default.
• W2007913595 countsByYear W20079135952015 @default.
• W2007913595 countsByYear W20079135952017 @default.
• W2007913595 countsByYear W20079135952018 @default.
• W2007913595 countsByYear W20079135952019 @default.
• W2007913595 countsByYear W20079135952021 @default.
• W2007913595 countsByYear W20079135952022 @default.
• W2007913595 crossrefType "journal-article" @default.
• W2007913595 hasAuthorship W2007913595A5001811866 @default.
• W2007913595 hasAuthorship W2007913595A5009021448 @default.
• W2007913595 hasAuthorship W2007913595A5010765538 @default.
• W2007913595 hasAuthorship W2007913595A5021121886 @default.
• W2007913595 hasAuthorship W2007913595A5036293904 @default.
• W2007913595 hasAuthorship W2007913595A5041566320 @default.
• W2007913595 hasAuthorship W2007913595A5050620740 @default.
• W2007913595 hasAuthorship W2007913595A5053487646 @default.
• W2007913595 hasAuthorship W2007913595A5053607123 @default.
• W2007913595 hasAuthorship W2007913595A5079168682 @default.
• W2007913595 hasAuthorship W2007913595A5081862103 @default.
• W2007913595 hasAuthorship W2007913595A5085974329 @default.
• W2007913595 hasBestOaLocation W20079135951 @default.
• W2007913595 hasConcept C104317684 @default.
• W2007913595 hasConcept C111829193 @default.
• W2007913595 hasConcept C2778461978 @default.
• W2007913595 hasConcept C41091548 @default.
• W2007913595 hasConcept C501734568 @default.
• W2007913595 hasConcept C502942594 @default.
• W2007913595 hasConcept C54355233 @default.
• W2007913595 hasConcept C54458228 @default.
• W2007913595 hasConcept C67705224 @default.
• W2007913595 hasConcept C86803240 @default.
• W2007913595 hasConceptScore W2007913595C104317684 @default.
• W2007913595 hasConceptScore W2007913595C111829193 @default.
• W2007913595 hasConceptScore W2007913595C2778461978 @default.
• W2007913595 hasConceptScore W2007913595C41091548 @default.
• W2007913595 hasConceptScore W2007913595C501734568 @default.
• W2007913595 hasConceptScore W2007913595C502942594 @default.
• W2007913595 hasConceptScore W2007913595C54355233 @default.
• W2007913595 hasConceptScore W2007913595C54458228 @default.
• W2007913595 hasConceptScore W2007913595C67705224 @default.
• W2007913595 hasConceptScore W2007913595C86803240 @default.
• W2007913595 hasIssue "11" @default.
• W2007913595 hasLocation W20079135951 @default.
• W2007913595 hasLocation W20079135952 @default.
• W2007913595 hasLocation W20079135953 @default.
• W2007913595 hasLocation W20079135954 @default.
• W2007913595 hasLocation W20079135955 @default.
• W2007913595 hasOpenAccess W2007913595 @default.
• W2007913595 hasPrimaryLocation W20079135951 @default.
• W2007913595 hasRelatedWork W1562693820 @default.
• W2007913595 hasRelatedWork W1895018249 @default.
• W2007913595 hasRelatedWork W2005867936 @default.
• W2007913595 hasRelatedWork W2068588654 @default.
• W2007913595 hasRelatedWork W2085975240 @default.
• W2007913595 hasRelatedWork W2098325466 @default.
• W2007913595 hasRelatedWork W2135257384 @default.
• W2007913595 hasRelatedWork W2384774992 @default.
• W2007913595 hasRelatedWork W2385130702 @default.
• W2007913595 hasRelatedWork W4315629143 @default.
• W2007913595 hasVolume "3" @default.
• W2007913595 isParatext "false" @default.
• W2007913595 isRetracted "false" @default.

• next